Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.88 |
| ▸ | PTPRC | P08575 | 2/20 | 0.59 |
| ▸ | CDC25B | P30305 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 7/20 | 0.49 |
| ▸ | CES1 | P23141 | 7/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10446698 | 0.88 | PTPN1 (0.68) | PTPN1PTPRCCDC25BALOX5ALDH1A1 | |
| SCHEMBL13611359 | 0.86 | PTPN1 (0.69) | PTPN1PTPRCCDC25BCES2CES1 | |
| SCHEMBL5596353 | 0.85 | PTPN1 (0.68) | PTPN1PTPRCCDC25BCES2CES1 | |
| SCHEMBL5595620 | 0.84 | PTPRC (0.69) | PTPN1PTPRCCDC25BCES2CES1 | |
| SCHEMBL4289068 | 0.84 | PTPN1 (0.68) | PTPN1PTPRCCDC25BCES2CES1 | |
| SCHEMBL5595788 | 0.84 | PTPN1 (0.68) | PTPN1PTPRCCDC25BCES2CES1 | |
| SCHEMBL4299667 | 0.84 | PTPN1 (0.68) | PTPN1PTPRCCDC25BCES2CES1 | |
| SCHEMBL5595746 | 0.84 | PTPRC (0.69) | PTPN1PTPRCCDC25BCES2CES1 | |
| SCHEMBL4298282 | 0.84 | PTPN1 (0.67) | PTPN1PTPRCCDC25BCES2CES1 | |
| SCHEMBL4294847 | 0.83 | PTPRC (0.71) | PTPN1PTPRCCDC25BCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CELLGATE, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CELLGATE, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CELLGATE, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1185493-B1 | QUINONES FOR TREATMENT OF DISEASES | SLIL BIOMEDICAL CORP (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20050010060-A1 | Novel quinones as disease therapies | SLIL BIOMEDICAL CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| US-6809176-B2 | Quinones as disease therapies | SLIL BIOMEDICAL, CORPORATION | 2004-10-26 | — | — | US | disclosed |
| US-20040006049-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | SLIL BIOMEDICAL CORPORATION (US) | 2004-01-08 | — | — | US | disclosed |
| US-6649587-B1 | Cytostatic or cytocidal componenet conjugated to a polypeptide recognized and cleaved by enzymes such as prostate specific antigen (PSA) and cathepsin B | SLIL BIOMEDICAL CORPORATION | 2003-11-18 | — | — | US | disclosed |
| US-20030013677-A1 | QUINONES AS DISEASE THERAPIES | CELLGATE, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20020183512-A1 | Novel quinones as disease therapies | SLIL BIOMEDICAL CORPORATION | 2002-12-05 | — | — | US | disclosed |
| US-6482943-B1 | Quinones as disease therapies | SLIL BIOMEDICAL CORPORATION | 2002-11-19 | — | — | US | disclosed |
| EP-1173223-A2 | CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | Slil Biomedical Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066175-A2 | CONJUGATES AS THERAPIES FOR CANCER AND PROSTATE DISEASES | SLIL BIOMEDICAL CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010060-A1 | Novel quinones as disease therapies | NQO1, NDUFV2, SDHB | PTPN1 3247/4885PTPRC 1827/4885CDC25B 1302/4885 |
| US-20040006049-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CTSB, CTSL, CTSV | PTPN1 4034/4885PTPRC 1675/4885CDC25B 511/4885 |
| US-20030013677-A1 | QUINONES AS DISEASE THERAPIES | NQO1, NDUFV2, SDHB | PTPN1 3153/4885PTPRC 1718/4885CDC25B 1217/4885 |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, KLK3, FOLH1 | PTPN1 3701/4885PTPRC 1472/4885CDC25B 190/4885 |
| US-20020183512-A1 | Novel quinones as disease therapies | NQO1, NDUFV2, SDHB | PTPN1 3247/4885PTPRC 1827/4885CDC25B 1302/4885 |
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, CTSL, CTSV | PTPN1 4034/4885PTPRC 1675/4885CDC25B 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.